Sinovac Biotech, Other Current Liabilities

Sinovac Biotech,'s other current liabilities stands at $1.2B as of December 2025. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether Sinovac Biotech,'s other current liabilities is expanding or contracting. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Sinovac Biotech,'s other current liabilities evolved across reporting periods, while the comparison chart places SVA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. Sinovac Biotech,'s reading of $1.2B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.